Compare C3.ai Inc (AI) vs McKesson Corporation (MCK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
C3.ai Inc vs McKesson Corporation — how do they compare? C3.ai Inc trades at $8.85 (market cap $1.39B), while McKesson Corporation trades at $817.69 (market cap $94.52B). The key difference: McKesson Corporation is far larger — about 68× C3.ai Inc's market cap, and McKesson Corporation pays a 0.41% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| AI | MCK | |
|---|---|---|
Market Cap | $1.39B | $94.52B |
Sector | Technology | Health |
52-Week High | $29.16 | $995.69 |
52-Week Low | $7.76 | $659.01 |
Enterprise Value | $818.29M | $99.16B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai trades at $8.93, down 1.43% with bearish technical signals. The company shows revenue growth to $389M in 2025 but continues significant losses with -$289M net income. Analyst sentiment is mixed with 21% buy ratings and consensus target of $10.20. Recent developments include board member Jim Hagemann Snabe's appointment as European Commission Special Envoy for Industrial AI.
While revenue growth presents opportunity, persistent losses and negative cash flow pose substantial risk. The stock faces headwinds from unprofitability despite beating some earnings estimates. Upside potential exists if the company can accelerate path to profitability amid growing enterprise AI adoption.
McKesson (MCK) trades at $807.33, up 2.67% with strong bullish momentum. The stock shows robust fundamentals with consistent earnings beats and revenue growth from $309B to $359B in 2025. Technical indicators signal bullish momentum with price above key support levels. Recent news highlights McKesson's growth in specialty pharma and oncology services, supported by positive analyst sentiment.
Outlook remains positive with 80% analyst buy ratings and $932.83 consensus price target, offering 15% upside. Risks include policy pressures and margin compression, but diversified portfolio and investment-grade rating provide stability. Earnings momentum and strategic investments position MCK for continued growth in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
